SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bhag Karamchandani who wrote (4264)5/7/1998 2:51:00 PM
From: Peter Singleton  Read Replies (1) of 6136
 
Bhag, I think Peter Johnson was referring to AG3340 as a second generation MMP inhibitor, in the context of BBIOY's Marimastat as a first generation product. As AGPH as pointed out, there are a family of MMP's which perform a variety of functions. AG3340 has apparently a much higher therapeutic index than Marimastat. It inhibits the desired MMP's (those implicated in cancer) to a greater extent, and it minimally inhibits the MMP's that perform other, necessary, tasks.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News